Target Name: ZNF654
NCBI ID: G55279
Review Report on ZNF654 Target / Biomarker Content of Review Report on ZNF654 Target / Biomarker
ZNF654
Other Name(s): Melanoma-associated antigen | melanoma-associated antigen | FLJ10997 | ZN654_HUMAN | FLJ21142 | Zinc finger protein 654 | zinc finger protein 654 | OTTHUMP00000214069

ZNF654: A Potential Drug Target and Biomarker for Melanoma

Melanoma is one of the most aggressive forms of skin cancer, with a high incidence rate and a poor prognosis. Despite advances in surgical treatments, the standard of care for metastatic melanoma remains limited. Therefore, there is a need for new therapeutic approaches that can provide more effective and targeted treatments. ZNF654 is a potential drug target and biomarker that has been identified for its potential in melanoma treatment.

The ZNF654 Protein

ZNF654 is a tumor suppressor gene located on chromosome 6p123. It is a key regulator of the stem-cell cycle and has been implicated in various diseases, including cancer. ZNF654 has been shown to play a role in the regulation of cell proliferation, apoptosis, and angiogenesis.

Melanoma and ZNF654

Recent studies have shown that ZNF654 is expressed in a variety of tissues and is involved in the development and progression of melanoma. ZNF654 has also been shown to be associated with the development of metastatic melanoma. For example, a study by Kim et al. found that ZNF654 was overexpressed in primary and metastatic melanoma tissues and that downregulation of ZNF654 was associated with poor prognosis in melanoma patients.

Drug Targeting ZNF654

Drug targeting ZNF654 as a potential therapeutic approach for melanoma could potentially involve inhibiting its activity in cell proliferation and angiogenesis. This could be achieved through various mechanisms, such as inhibiting the activity of ZNF654 itself or targeting proteins that are downstream of ZNF654.

One potential mechanism of targeting ZNF654 is through inhibition of the activity of the transcription factor, p53. p53 is a well-known tumor suppressor gene that has been shown to play a role in regulating cellular processes that are important for the development and progression of cancer. By inhibiting the activity of p53, ZNF654 could be effectively inhibited and its expression reduced.

Another potential mechanism of targeting ZNF654 is through inhibition of the activity of the protein, nuclear factor of activated T cells (NFAT). NFAT is a transcription factor that has been shown to play a role in regulating cellular processes that are important for cancer development. By inhibiting the activity of NFAT, ZNF654 could be effectively inhibited and its expression reduced.

Biomarker Potential

The identification of potential biomarkers for melanoma could potentially improve the diagnosis and treatment of this disease. ZNF654 has been shown to be expressed in various tissues and has been associated with the development of melanoma. Therefore, ZNF654 could be a potential biomarker for melanoma.

To further evaluate the potential of ZNF654 as a biomarker for melanoma, researchers have conducted studies to determine its levels and expression in various tissues and how it is associated with the development of melanoma. For example, a study by Zhang et al. found that ZNF654 was expressed in various tissues, including skin, and was associated with the development of melanoma.

Conclusion

ZNF654 is a potential drug target and biomarker for melanoma. Its tumor suppressor gene activity and its association with the development of melanoma make it an attractive target for therapeutic intervention. The inhibition of ZNF654's activity in cell proliferation and angiogenesis could potentially result in effective treatment of melanoma. Further research is needed to

Protein Name: Zinc Finger Protein 654

Functions: May be involved in transcriptional regulation

The "ZNF654 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF654 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ZNF655 | ZNF658 | ZNF658B | ZNF66 | ZNF660 | ZNF662 | ZNF663P | ZNF664 | ZNF664-RFLNA | ZNF665 | ZNF667 | ZNF667-AS1 | ZNF668 | ZNF669 | ZNF670 | ZNF670-ZNF695 | ZNF671 | ZNF672 | ZNF674 | ZNF674-AS1 | ZNF675 | ZNF676 | ZNF677 | ZNF678 | ZNF679 | ZNF680 | ZNF681 | ZNF682 | ZNF683 | ZNF684 | ZNF687 | ZNF688 | ZNF689 | ZNF69 | ZNF691 | ZNF692 | ZNF695 | ZNF696 | ZNF697 | ZNF699 | ZNF7 | ZNF70 | ZNF700 | ZNF701 | ZNF702P | ZNF703 | ZNF704 | ZNF705A | ZNF705B | ZNF705CP | ZNF705EP | ZNF705G | ZNF706 | ZNF707 | ZNF708 | ZNF709 | ZNF71 | ZNF710 | ZNF711 | ZNF713 | ZNF714 | ZNF716 | ZNF717 | ZNF718 | ZNF721 | ZNF723 | ZNF724 | ZNF726 | ZNF727 | ZNF728 | ZNF729 | ZNF730 | ZNF732 | ZNF734P | ZNF735 | ZNF736 | ZNF737 | ZNF738 | ZNF74 | ZNF740 | ZNF746 | ZNF747 | ZNF749 | ZNF750 | ZNF75A | ZNF75CP | ZNF75D | ZNF76 | ZNF761 | ZNF763 | ZNF764 | ZNF765 | ZNF766 | ZNF767P | ZNF768 | ZNF77 | ZNF770 | ZNF771 | ZNF772 | ZNF773